Target Name: SLK
NCBI ID: G9748
Other Name(s): CTCL tumor antigen se20-9 | MGC133067 | STE20-related kinase | Serine/threonine-protein kinase 2 | STE20-like serine/threonine-protein kinase (isoform 1) | STE20-like kinase | STE20 like kinase, transcript variant 1 | LOSK | KIAA0204 | BA16H23.1 | STE20-related serine/threonine-protein kinase | OTTHUMP00000020426 | STE20-like serine/threonine-protein kinase | OTTHUMP00000020425 | SNF1 sucrose nonfermenting like kinase | Long Ste20-like Kinase | SLK_HUMAN | se20-9 | Ste20-related serine/threonine kinase | Se20-9 | HSLK | serine/threonine-protein kinase 2 | bA16H23.1 | hSLK | STE20 like kinase | STK2 | SNF1 (sucrose nonfermenting, yeast, homolog)-like kinase, SNF1 sucrose nonfermenting like kinase | SLK variant 1

SLK: A Potential Drug Target and Biomarker for Cancer

SLK (CTCL tumor antigen se20-9) is a protein that is expressed in various tissues, including the brain, lung, liver, and gastrointestinal tract. It is also a potential drug target and biomarker for various diseases, including cancer.

The protein encoded by the SLK gene is a member of the immunoglobulin superfamily and has a molecular weight of approximately 180 kDa. It consists of two heavy chains and two light chains that are held together by disulfide bonds. The heavy chains contain four constant (C) regions and one variable (V) region, while the light chains contain one variable (V) region and one constant (C) region.

SLK is highly expressed in various tissues and is expressed in the brain, lung, liver, and gastrointestinal tract, among others. It has been shown to be involved in various physiological processes, including cell signaling, inflammation, and immune responses.

SLK has also been shown to be a potential drug target and biomarker for various diseases, including cancer. For example, studies have shown that inhibiting SLK can lead to increased cell proliferation and survival in cancer cells. Additionally, SLK has been shown to be overexpressed in various types of cancer, including breast, lung, and ovarian cancer.

In addition to its potential as a drug target, SLK has also been shown to be a potential biomarker for cancer. For example, studies have shown that the expression of SLK is associated with the development and progression of various types of cancer. Additionally, SLK has been shown to be a useful marker for evaluating the effectiveness of cancer treatments.

Overall, SLK is a protein that has important roles in various physiological processes and has been shown to be involved in the development and progression of cancer. As a potential drug target and biomarker, SLK is a promising target for future research and clinical trials.

Protein Name: STE20 Like Kinase

Functions: Mediates apoptosis and actin stress fiber dissolution

More Common Targets

SLMAP | SLMO2-ATP5E | SLN | SLPI | SLTM | SLU7 | SLURP1 | SLURP2 | SLX1A | SLX1A-SULT1A3 | SLX1B | SLX1B-SULT1A4 | SLX4 | SLX4IP | SLX9 | SMAD | SMAD1 | SMAD1-AS1 | SMAD1-AS2 | SMAD2 | SMAD3 | SMAD4 | SMAD5 | SMAD5-AS1 | SMAD6 | SMAD7 | SMAD9 | SMAGP | Small Conductance Calcium-Activated Potassium Channel (SK) | SMAP1 | SMAP2 | SMARCA1 | SMARCA2 | SMARCA4 | SMARCA5 | SMARCAD1 | SMARCAD1-DT | SMARCAL1 | SMARCAL1-AS1 | SMARCB1 | SMARCC1 | SMARCC2 | SMARCD1 | SMARCD2 | SMARCD3 | SMARCE1 | SMC1A | SMC1B | SMC2 | SMC2-DT | SMC3 | SMC4 | SMC5 | SMC5-DT | SMC5-SMC6 Complex | SMC6 | SMCHD1 | SMCO1 | SMCO2 | SMCO3 | SMCO4 | SMCP | SMCR2 | SMCR5 | SMCR8 | SMDT1 | SMG1 | SMG1P1 | SMG1P2 | SMG1P3 | SMG1P4 | SMG1P5 | SMG5 | SMG6 | SMG7 | SMG7-AS1 | SMG8 | SMG9 | SMILR | SMIM1 | SMIM10 | SMIM10L1 | SMIM10L2A | SMIM10L2B | SMIM11 | SMIM12 | SMIM13 | SMIM14 | SMIM15 | SMIM17 | SMIM18 | SMIM19 | SMIM2 | SMIM2-AS1 | SMIM2-IT1 | SMIM20 | SMIM21 | SMIM22 | SMIM23 | SMIM24